Shielding Infants: A Deep Dive into AAP's RSV Prevention Guidelines

In this episode, we explore the American Academy of Pediatrics' latest recommendations for preventing RSV disease in infants and children. With the FDA's recent approval of nirsevimab—a long-acting monoclonal antibody—parents can feel empowered in the fight against this dangerous virus. Discover who qualifies for nirsevimab, its advantages over palivizumab, and the importance of timely access for high-risk babies. Join us as we discuss how to protect our littlest ones and ensure they stay healthy this RSV season!